BETHESDA, MD, July 15, 2015 — Evidera would like to extend an enthusiastic congratulations to the COPD Foundation and their COPD Biomarker Qualification Consortium (CBQC) on their work leading to the qualification of plasma fibrinogen as the first biomarker for COPD by the U.S. Food and Drug Administration (FDA). The use of this biomarker is expected to make it easier to identify patients that may be at a higher risk of exacerbation or mortality for inclusion in interventional clinical trials.
Evidera was honored to be among the many collaborators in this process, helping to design, conduct and interpret the analyses required to establish this biomarker as useful. More information on these analyses may be found in a recent issue of the Journal of the COPD Foundation, or by contacting [email protected].
For more information on the CBQC or the qualification of plasma fibrinogen please see the COPD Foundation press release. For more information on the FDA Biomarker Qualification Program please visit the FDA website.
Evidera, a wholly owned subsidiary of Symphony Technology Group, provides health economic, outcomes research, market access, data analytic and epidemiology services to life sciences organizations worldwide. For more information, visit www.evidera.com.
Susan Potter Couch, Director, Marketing & Communications
+1 301 664 7286